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As the era of precision and personalized medicine is gaining
exponential positive gain in the field of medicine, there is a
positive shift towards a more evidence-based patient care
approach for patients with hepatological diseases. One factor that is crucial in any physician’s decision-making efforts
involves the application of novel innovative approaches that
can enhance predicting survival outcome. Acute-on-chronic
liver failure (ACLF) is a perfect example of how liver can
rapidly deteriorate, and the hepatitis B virus (HBV) is one
crucial culprit. Patients can experience organ failure that
leads to their mortality, and in this article the authors clearly
described the use of backward stepwise logistic regression
(LR) and classification and regression tree (CART) analysis
to derive two predictive models and then compared them
with the model of end-stage liver disease (MELD) score for
novel prognostic models of the 180-day outcome for patients with HBV-ACLF.
This innovative study showed the novel predictive models
to be superior to MELD score, providing Hepatologists and
Gastroenterologists with a new guiding technique in their
evidence-based patient-centered care approach for their
clinical treatment decision-making. Of note, one of the leading causes of chronic liver failure in Asia is HBV1 and the
current leading therapeutical intervention for cure is liver
transplantation (LT).2–4
However, due to decline of health of patients with ACLF,
some of the patients become delisted from the organ transplantation list because they are not well enough to undergo
LT. Currently, MELD score is the most used for patients on
the LT list, although several other scoring modalities are
available.5 Current and recent advancements in Hepatol-

ogy generated the finding for HBV-ACLF having a window
of 30 to 90 days, with respect to the scoring system used.
In the article of interest, the authors introduced a predictive module of 180-day outcome for patients based upon
multiple variables that are not currently used in the MELD
score. Also, there are other scoring systems that have been
introduced for HBV-ACLF recently; although, the authors
created a CART system scoring that is easier for the clinician to interpret and, in turn, for the patient to receive
the paramount care they deserve. Ultimately, the research
demonstrated that both LR and the CART model appeared
to perform better than the MELD score.
There are, however, some factors and limitations within
the study (as properly mentioned in the article), ranging
from not having a mid-data report and not having a larger
cohort for studying their novel scoring models. I believe if
a consensus can be developed by having multiple LT centers around the globe adapt this novel scoring module, we
can achieve a better understanding and more precise scoring system developed for patients with HBV-ACLF requiring
LT. These novel models which the authors have described
and investigated may be helpful for Transplant Hepatologists, Gastroenterologists and Health Care teams who need
to make essential clinical decisions for patients with HBVACLF.
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